Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Christopher R. Shubert

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6472-2350; OpenAlex author ID A5074581605. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
80
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 4 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 4 papers

Papers 19

  1. Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2026.102359↗
  2. Integrated driver gene-based survival prediction in resected pancreatic cancer. Co-author DOI 10.1093/bjs/znag123↗
  3. Patient-derived Organoid Pharmacotyping as a Predictive Tool for Therapeutic Selection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006517↗
  4. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  5. The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Su… Co-author DOI 10.1097/sla.0000000000006794↗
  6. The Organ-Specific Prognostic Value of TP53 Mutations in Pancreatic Cancer Patients with Oligometastasis Following Surgical Resection. Co-author DOI 10.1097/sla.0000000000006823↗
  7. Sociodemographic variation in the utilization of minimally invasive surgical approaches for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2024.07.403↗
  8. Clinical Relevance of Cancerization of Ducts in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002326↗
  9. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05476-w↗
  10. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
  11. Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mco2.184↗
  12. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-022-06667-x↗
  13. The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. Co-author DOI 10.1067/j.cpradiol.2022.05.001↗
  14. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  15. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. Co-author DOI 10.1002/cam4.4144↗
  16. Patient Selection for Neoadjuvant Therapy in Early-Stage Pancreatic Cancer. First author DOI 10.1200/jco.2016.71.2315↗
  17. Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5762-6↗
  18. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and a… Co-author DOI 10.1016/j.jamcollsurg.2016.02.009↗
  19. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chem… Co-author DOI 10.1016/j.surg.2016.06.010↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kelly J. Lafaro · 14 shared papers, 2022–2026 · strength 2.58
  2. Richard Andrew Burkhart · 12 shared papers, 2022–2026 · strength 2.13
  3. Jin Peng He · 12 shared papers, 2022–2026 · strength 2.11
  4. William R. Burns · 8 shared papers, 2022–2024 · strength 1.21
  5. William Reece Burns · 5 shared papers, 2025–2026 · strength 1.12
  6. Lei Zheng · 7 shared papers, 2022–2026 · strength 1.07
  7. Elizabeth M. Jaffee · 4 shared papers, 2022–2026 · strength 0.79
  8. Ralph H. Hruban · 4 shared papers, 2022–2026 · strength 0.75
  9. Joseph R. Habib · 5 shared papers, 2022–2024 · strength 0.70
  10. Brady A. Campbell · 3 shared papers, 2025–2026 · strength 0.70
  11. Jacquelyn W. Zimmerman · 4 shared papers, 2022–2026 · strength 0.68
  12. Sami Shoucair · 4 shared papers, 2022–2023 · strength 0.58
  13. Benedict Kinny‐Köster · 4 shared papers, 2022–2024 · strength 0.55
  14. Sagar D. Patel · 2 shared papers, 2025–2026 · strength 0.48
  15. Marco Dal Molin · 2 shared papers, 2025–2026 · strength 0.47
  16. Richard A. Burkhart · 2 shared papers, 2025–2026 · strength 0.45
  17. Ammar A. Javed · 3 shared papers, 2022–2024 · strength 0.45
  18. Elana Judith Fertig · 2 shared papers, 2026 · strength 0.43
  19. Samantha R. Guinn · 2 shared papers, 2026 · strength 0.43
  20. Norman G. Nicolson · 2 shared papers, 2026 · strength 0.43
  21. Christopher L. Wolfgang · 3 shared papers, 2022–2023 · strength 0.41
  22. John R. Bergquist · 5 shared papers, 2016–2021 · strength 0.39
  23. Mark Joseph Truty · 5 shared papers, 2016–2021 · strength 0.39
  24. Daniel A. Laheru · 2 shared papers, 2022–2026 · strength 0.36
  25. Toni T. Seppälä · 2 shared papers, 2022–2026 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.